Don’t you love it when the good ones get recognized!
👏Bravo, @viveksubbiah.bsky.social Subbiah, on being Clarivate Highly Cited Researcher! He blocks 30m after his talks to ensure he gets to discuss w every person who comes up to him after! Way to advance oncology drug development! 👏
📷 #ESMO24
👏Bravo, @viveksubbiah.bsky.social Subbiah, on being Clarivate Highly Cited Researcher! He blocks 30m after his talks to ensure he gets to discuss w every person who comes up to him after! Way to advance oncology drug development! 👏
📷 #ESMO24
November 23, 2024 at 3:26 PM
Don’t you love it when the good ones get recognized!
👏Bravo, @viveksubbiah.bsky.social Subbiah, on being Clarivate Highly Cited Researcher! He blocks 30m after his talks to ensure he gets to discuss w every person who comes up to him after! Way to advance oncology drug development! 👏
📷 #ESMO24
👏Bravo, @viveksubbiah.bsky.social Subbiah, on being Clarivate Highly Cited Researcher! He blocks 30m after his talks to ensure he gets to discuss w every person who comes up to him after! Way to advance oncology drug development! 👏
📷 #ESMO24
#BLADDR24 #ESMO24 highlights
➡️ Adj CKI post cystectomy
➡️ SUNRISE IV - can neoadjuvant non-platinum treatment be used?
➡️ Trials of perioperative combos
@oncoalert.bsky.social
➡️ Adj CKI post cystectomy
➡️ SUNRISE IV - can neoadjuvant non-platinum treatment be used?
➡️ Trials of perioperative combos
@oncoalert.bsky.social
November 27, 2024 at 9:31 AM
#BLADDR24 #ESMO24 highlights
➡️ Adj CKI post cystectomy
➡️ SUNRISE IV - can neoadjuvant non-platinum treatment be used?
➡️ Trials of perioperative combos
@oncoalert.bsky.social
➡️ Adj CKI post cystectomy
➡️ SUNRISE IV - can neoadjuvant non-platinum treatment be used?
➡️ Trials of perioperative combos
@oncoalert.bsky.social
Proud to serve as co-PI of this global assessment of #NSCLC biomarker testing experiences among patients and caregivers, presented at #ESMO24 #LCSM cor2ed.com/precision-on...
Biomarker testing in NSCLC: patient and caregiver awareness and understanding | COR2ED
We are pleased to share findings from a PRECISION ONCOLOGY CONNECT survey that were presented as a poster at ESMO 2024. A group of international
cor2ed.com
November 28, 2024 at 1:30 PM
Proud to serve as co-PI of this global assessment of #NSCLC biomarker testing experiences among patients and caregivers, presented at #ESMO24 #LCSM cor2ed.com/precision-on...
It would be nice to build a biotech community on this site. In three weeks I’ll be attending #ESMO24 and I’ll post some content here. Let’s see if we can bring some coverage of the conference here
August 24, 2024 at 12:35 PM
It would be nice to build a biotech community on this site. In three weeks I’ll be attending #ESMO24 and I’ll post some content here. Let’s see if we can bring some coverage of the conference here
Tracking #MASCC24 and #ESMO24 updates along with planning for a #UK 🇬🇧 holiday next month has me grateful for our global 🌐 family on #BowTieFriday
@docwithbowtie.bsky.social
@ctsinclair.bsky.social
@engagetheo.bsky.social
@pinkprincess.bsky.social
CanSky MedSky hapc hpm
@docwithbowtie.bsky.social
@ctsinclair.bsky.social
@engagetheo.bsky.social
@pinkprincess.bsky.social
CanSky MedSky hapc hpm
June 28, 2024 at 12:38 PM
Tracking #MASCC24 and #ESMO24 updates along with planning for a #UK 🇬🇧 holiday next month has me grateful for our global 🌐 family on #BowTieFriday
@docwithbowtie.bsky.social
@ctsinclair.bsky.social
@engagetheo.bsky.social
@pinkprincess.bsky.social
CanSky MedSky hapc hpm
@docwithbowtie.bsky.social
@ctsinclair.bsky.social
@engagetheo.bsky.social
@pinkprincess.bsky.social
CanSky MedSky hapc hpm
Did you miss out on #ESMO24 this year? No worries! This recent episode of CancerSpeak has you covered 📻 Topics include advances in melanoma, immunotherapy, and the role of social media in clinical oncology and patient advocacy. @oncoalert.bsky.social #OncSky
cancerspeak.podbean.com/e/key-highli...
cancerspeak.podbean.com/e/key-highli...
November 26, 2024 at 7:25 PM
Did you miss out on #ESMO24 this year? No worries! This recent episode of CancerSpeak has you covered 📻 Topics include advances in melanoma, immunotherapy, and the role of social media in clinical oncology and patient advocacy. @oncoalert.bsky.social #OncSky
cancerspeak.podbean.com/e/key-highli...
cancerspeak.podbean.com/e/key-highli...
Great 1st day at #ESMO24 @myesmo.bsky.social
October 17, 2025 at 4:42 PM
Great 1st day at #ESMO24 @myesmo.bsky.social
At #ESMO24 this week, Prof Christina B Yap presented 'How much do real world patients really differ from clinical trials?' in the session on How Real World Data (RWD) are transforming oncology.
September 20, 2024 at 3:11 PM
At #ESMO24 this week, Prof Christina B Yap presented 'How much do real world patients really differ from clinical trials?' in the session on How Real World Data (RWD) are transforming oncology.
Fall makes for #FunTieFriday on #BowTieFriday. So much amazing science in #GIonc #PallOnc #SuppOnc happening at #ESMO24 this week. What puts color in your life?
@docwithbowtie.bsky.social
@ctsinclair.bsky.social
@engagetheo.bsky.social
@pinkprincess.bsky.social
CanSky MedSky hapc hpm
September 13, 2024 at 7:59 PM
Fall makes for #FunTieFriday on #BowTieFriday. So much amazing science in #GIonc #PallOnc #SuppOnc happening at #ESMO24 this week. What puts color in your life?
@docwithbowtie.bsky.social
@ctsinclair.bsky.social
@engagetheo.bsky.social
@pinkprincess.bsky.social
CanSky MedSky hapc hpm
The benchmark for $JANX's prostate cancer data release tomorrow is the STEAP1xCD3 results that $AMGN presented at #ESMO24
In summary:
- 53% PSA50, with 59% DOR at 3mo and 6% at 6mo
- 34% PSA90, 29% ORR, mRPFS 7.8mo
- 72% Gr3 AEs, 76% CRS, 69% musculoskeletal events
In summary:
- 53% PSA50, with 59% DOR at 3mo and 6% at 6mo
- 34% PSA90, 29% ORR, mRPFS 7.8mo
- 72% Gr3 AEs, 76% CRS, 69% musculoskeletal events
December 1, 2024 at 3:03 PM
The benchmark for $JANX's prostate cancer data release tomorrow is the STEAP1xCD3 results that $AMGN presented at #ESMO24
In summary:
- 53% PSA50, with 59% DOR at 3mo and 6% at 6mo
- 34% PSA90, 29% ORR, mRPFS 7.8mo
- 72% Gr3 AEs, 76% CRS, 69% musculoskeletal events
In summary:
- 53% PSA50, with 59% DOR at 3mo and 6% at 6mo
- 34% PSA90, 29% ORR, mRPFS 7.8mo
- 72% Gr3 AEs, 76% CRS, 69% musculoskeletal events
ESMO 2024 Le PIONeeR Project présente pour la première fois les résultats de son étude clinique de phase Ib/IIa. fr.ap-hm.fr/actu/esmo-20... #ESMO24 #PIONeeRProject #Oncologie #Immunothérapie #RechercheMédicale #NSCLC #CancerDuPoumon #InnovationSanté #Phase1b2a #EssaiClinique #RHU #Marseille
September 17, 2024 at 5:48 PM
ESMO 2024 Le PIONeeR Project présente pour la première fois les résultats de son étude clinique de phase Ib/IIa. fr.ap-hm.fr/actu/esmo-20... #ESMO24 #PIONeeRProject #Oncologie #Immunothérapie #RechercheMédicale #NSCLC #CancerDuPoumon #InnovationSanté #Phase1b2a #EssaiClinique #RHU #Marseille
Retifanlimab Emerges as Potential New SOC in Advanced SCAC #oncology #ESMO24 www.onclive.com/view/retifan...
Retifanlimab Emerges as Potential New SOC in Advanced SCAC
Sheela Rao, MBBS, MD, FRCP, discusses data from the phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab plus chemotherapy vs chemotherapy in advanced SCAC.
www.onclive.com
January 7, 2025 at 10:41 PM
Retifanlimab Emerges as Potential New SOC in Advanced SCAC #oncology #ESMO24 www.onclive.com/view/retifan...
Combination Regimens Make Their Mark in Frontline HCC @danengle.bsky.social #ESMO24 #oncology
www.onclive.com/view/combina...
www.onclive.com/view/combina...
Combination Regimens Make Their Mark in Frontline HCC
In a Peer Exchange, HCC experts discussed how new data from the HIMALAYA, LEAP-012, EMERALD-1, and IMbrave050 trials could be used to optimize treatment.
www.onclive.com
December 24, 2024 at 1:07 PM
Combination Regimens Make Their Mark in Frontline HCC @danengle.bsky.social #ESMO24 #oncology
www.onclive.com/view/combina...
www.onclive.com/view/combina...
🔥@onclive.bsky.social🆙
✅Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations
🎯RWD based on @guardanthealth.bsky.social INFORM
👥Dr. Xiuning le
#LCSM @oncoalert.bsky.social #EGFR #ESMO24
www.onclive.com/view/real-wo...
✅Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations
🎯RWD based on @guardanthealth.bsky.social INFORM
👥Dr. Xiuning le
#LCSM @oncoalert.bsky.social #EGFR #ESMO24
www.onclive.com/view/real-wo...
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
Dr. Xiuning Le highlights real-world data on therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations, emphasizing the need for improved treatments, at ESMO Congress 2...
www.onclive.com
January 5, 2025 at 1:24 PM
🔥@onclive.bsky.social🆙
✅Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations
🎯RWD based on @guardanthealth.bsky.social INFORM
👥Dr. Xiuning le
#LCSM @oncoalert.bsky.social #EGFR #ESMO24
www.onclive.com/view/real-wo...
✅Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations
🎯RWD based on @guardanthealth.bsky.social INFORM
👥Dr. Xiuning le
#LCSM @oncoalert.bsky.social #EGFR #ESMO24
www.onclive.com/view/real-wo...
#ESMO24 A summary of presentations that caught my eye:
- STX-478 inhibitor in PIK3CA mutant tumors
- BMS-986365 AR degrader/antagonist in mCRPC
- BNT327 PD-L1/VEGF in EGFR-mutated NSCLC
- NVL-655 inhibitor in ALK-mutated NSCLC
- Ponsegromab anti-GDF15 for cancer patients with cachexia
- STX-478 inhibitor in PIK3CA mutant tumors
- BMS-986365 AR degrader/antagonist in mCRPC
- BNT327 PD-L1/VEGF in EGFR-mutated NSCLC
- NVL-655 inhibitor in ALK-mutated NSCLC
- Ponsegromab anti-GDF15 for cancer patients with cachexia
September 20, 2024 at 10:33 AM
#ESMO24 A summary of presentations that caught my eye:
- STX-478 inhibitor in PIK3CA mutant tumors
- BMS-986365 AR degrader/antagonist in mCRPC
- BNT327 PD-L1/VEGF in EGFR-mutated NSCLC
- NVL-655 inhibitor in ALK-mutated NSCLC
- Ponsegromab anti-GDF15 for cancer patients with cachexia
- STX-478 inhibitor in PIK3CA mutant tumors
- BMS-986365 AR degrader/antagonist in mCRPC
- BNT327 PD-L1/VEGF in EGFR-mutated NSCLC
- NVL-655 inhibitor in ALK-mutated NSCLC
- Ponsegromab anti-GDF15 for cancer patients with cachexia
November is gastric cancer awareness month and we are sharing updates in the field ⭐
At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer.
👉See the video below! 👈
https://buff.ly/48WQh5R
#stcsm #gism
At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer.
👉See the video below! 👈
https://buff.ly/48WQh5R
#stcsm #gism
Long-term survivorship concerns of patients with esophageal and gastric cancer - VJOncology
Jessie Elliott, FRCS, PhD, Trinity St. James’s Cancer Institute, Dublin, Ireland, discusses the long-term survivorship concerns of patients with esophageal...
buff.ly
November 20, 2024 at 9:01 AM
November is gastric cancer awareness month and we are sharing updates in the field ⭐
At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer.
👉See the video below! 👈
https://buff.ly/48WQh5R
#stcsm #gism
At #ESMO24, we spoke with Jessie Elliott on long-term survivorship concerns of patients with esophageal and gastric cancer.
👉See the video below! 👈
https://buff.ly/48WQh5R
#stcsm #gism
Retroactive study presented at a conference over the weekend suggests that mRNA vaccines might boost the efficacy of cancer immunotherapy treatments. More work would need to be done to show if this is a real effect but it's interesting.
endpts.com/esmo24-in-su...
endpts.com/esmo24-in-su...
In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy
The mRNA-based Covid vaccines used by hundreds of millions of people may provide an unexpected benefit to some cancer patients, significantly improving survival when given within a few months of immun...
endpts.com
September 16, 2024 at 2:15 PM
Retroactive study presented at a conference over the weekend suggests that mRNA vaccines might boost the efficacy of cancer immunotherapy treatments. More work would need to be done to show if this is a real effect but it's interesting.
endpts.com/esmo24-in-su...
endpts.com/esmo24-in-su...
Some competition for $RVMD at #ESMO24. Astellas' KRAS G12D degrader shows 33% ORR at the highest dose (n=12), with 42% in PDAC (n=7). Still low n, but as a reference $RVMD had a 27% ORR in Ras-mutant PDAC
September 9, 2024 at 8:49 AM
Some competition for $RVMD at #ESMO24. Astellas' KRAS G12D degrader shows 33% ORR at the highest dose (n=12), with 42% in PDAC (n=7). Still low n, but as a reference $RVMD had a 27% ORR in Ras-mutant PDAC
NKT2152 Ushers in a New Era of HIF-2α Inhibition in Pretreated Advanced ccRCC
@drchoueiri.bsky.social @danafarbernews.bsky.social #ESMO24 #kcsm #oncology
www.onclive.com/view/nkt2152...
@drchoueiri.bsky.social @danafarbernews.bsky.social #ESMO24 #kcsm #oncology
www.onclive.com/view/nkt2152...
NKT2152 Ushers in a New Era of HIF-2α Inhibition in Pretreated Advanced ccRCC
Toni Choueiri, MD, discusses the unique features of NKT2152, the agent’s safety profile in RCC, and future research directions across GU oncology.
www.onclive.com
January 28, 2025 at 3:34 PM
NKT2152 Ushers in a New Era of HIF-2α Inhibition in Pretreated Advanced ccRCC
@drchoueiri.bsky.social @danafarbernews.bsky.social #ESMO24 #kcsm #oncology
www.onclive.com/view/nkt2152...
@drchoueiri.bsky.social @danafarbernews.bsky.social #ESMO24 #kcsm #oncology
www.onclive.com/view/nkt2152...
TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC @drchoueiri.bsky.social @danafarber.bsky.social #ESMO24 #kcsm #oncology www.onclive.com/view/tinivo-...
TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC
Toni Choueiri, MD, details the PFS outcomes and safety profiles for tivozanib plus nivolumab vs tivozanib alone in metastatic renal cell carcinoma
www.onclive.com
January 8, 2025 at 1:03 PM
TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC @drchoueiri.bsky.social @danafarber.bsky.social #ESMO24 #kcsm #oncology www.onclive.com/view/tinivo-...
November is gastric cancer awareness month and we are sharing updates in the field ⭐
At #ESMO24, we spoke with Filippo Pietrantonio on the final OS results from KEYNOTE-811 in HER2+ metastatic gastric cancer.
👉See the video below! 👈
https://buff.ly/4ezvhmz
#stcsm #gism
At #ESMO24, we spoke with Filippo Pietrantonio on the final OS results from KEYNOTE-811 in HER2+ metastatic gastric cancer.
👉See the video below! 👈
https://buff.ly/4ezvhmz
#stcsm #gism
Final overall survival results from KEYNOTE-811 in HER2+ metastatic gastric cancer - VJOncology
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the final overall survival (OS) analysis of the...
buff.ly
November 27, 2024 at 9:01 AM
November is gastric cancer awareness month and we are sharing updates in the field ⭐
At #ESMO24, we spoke with Filippo Pietrantonio on the final OS results from KEYNOTE-811 in HER2+ metastatic gastric cancer.
👉See the video below! 👈
https://buff.ly/4ezvhmz
#stcsm #gism
At #ESMO24, we spoke with Filippo Pietrantonio on the final OS results from KEYNOTE-811 in HER2+ metastatic gastric cancer.
👉See the video below! 👈
https://buff.ly/4ezvhmz
#stcsm #gism